The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma

SIMPLE SUMMARY: Glioblastoma (GBM) is the deadliest primary central nervous system (CNS) cancer in adults despite aggressive treatment. Once progressed, the prognosis is very poor and the effective traditional medicine treatment options are limited, so the management of recurrent glioblastoma (rGBM)...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xudong, Zhao, Zihui, Dai, Wufei, Liao, Kuo, Sun, Qi, Chen, Dongjiang, Pan, Xingxin, Feng, Lishuang, Ding, Ying, Wei, Shiyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486426/
https://www.ncbi.nlm.nih.gov/pubmed/37686584
http://dx.doi.org/10.3390/cancers15174308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486426/
https://www.ncbi.nlm.nih.gov/pubmed/37686584
http://dx.doi.org/10.3390/cancers15174308

Ejemplares similares